colab
we are not here to fit in
.png)
designed for
systems change
the cancer collaborative is a catalyst for change — where disruptive ideas and creative strategy come together to challenge systems, influence policy, and drive real impact for people affected by cancer.
access and reimbursement from the industry perspective, with mark oatway (astrazeneca canada)
precision oncology
#KNOWvember
the burden of cancer in canada
system & sustainability
crisis to catalyst
US cancer moonshot
system & sustainability
crisis to catalyst
gene therapy: international regulatory and health technology assessment (HTA) activities and reimbursement status
disruptive technologies
car t-cell therapy
beat cancer policy paper
system & sustainability
Beat Cancer Coalition
CDDF 2021. The Role of Patients in Drug Development and Innovation. From Patient Involvement to Patient Partnerships
system & sustainability
patient centricity
adoption of novel therapeutics in the canadian healthcare system. learnings from CAR T t cell therapy
HTA & value
car t-cell therapy
data collection in the age of RWE. HTA engagement. a colab series colabXpulseinfoframe
HTA & value
HTA & value
All.Can initiative improving efficiency in cancer care
system & sustainability
All.Can
patient centricity: why it matters
patient voice
DISRUPT
the need for collaboration in precision medicine, with TFRI digital health & discovery
precision oncology
#KNOWvember
EU beat cancer
system & sustainability
crisis to catalyst
economics of cancer
system & sustainability
crisis to catalyst
patient focused health policy
patient voice
cancer policy
Let’s put Patients at the front of
the line...Rapid access for Project
Orbis drugs could be a start. CAPT 2022
system & sustainability
access & innovation
improving access to innovative cancer therapies in canada
HTA & value
HTA & value
possible avenues to speed up patient access
HTA & value
HTA & value
canadian cancer clinical trials stakeholder charter
patient voice
PACT
international policies on the appropriate use of biosimilar drugs
system & sustainability
biosimilars
biosimilar drugs
system & sustainability
biosimilars
towards sustainable cancer care. reducing inefficiencies, improving outcomes. a policy report from the all.ca initiative
system & sustainability
All.Can
RHC 2025. The Evolution of Accelerated Access Pathways in Canada
system & sustainability
RHC
the importance of collaboration, with mark oatway (astrazeneca canada)
precision oncology
#KNOWvember
CBQA 2024. Precision Oncology in Cnada. Who Pays?
precision oncology
precision oncology & diagnostics
looking back to move forward. learning from the implementation of CAR T in canada
disruptive technologies
car t-cell therapy
US cancer moonshot
system & sustainability
crisis to catalyst
why we need to fix cancer care in canada now
system & sustainability
cancer action now alliance
it's time to put patients at the front of the line. rapid access for project orbis could be a start
HTA & value
HTA & value
patient and patient group engagement in cancer clinical trials. a stakeholder charter
patient voice
PACT
Adoption of Novel therapeutics in the Canadian
healthcare system: learnings from CAR T cell therapy
disruptive technologies
car t-cell therapy
HTA engagement
HTA & value
HTA & value
breast cancer & biosimilars
system & sustainability
biosimilars
CADTH review process for cell and gene therapies
disruptive technologies
car t-cell therapy